- Home
- NFBK vs LYEL Comparison
NFBK vs LYEL Comparison
Compare NFBK & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$23.70
Company Overview
Basic Information| Metric | NFBK | LYEL |
|---|---|---|
| Founded | 1887 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 545.4M | 490.1M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NFBK | LYEL |
|---|---|---|
| Price | $13.87 | $23.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $13.50 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 256.7K | 74.3K |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $6,870,000.00 | $36,000.00 |
| Revenue This Year | $4.95 | N/A |
| Revenue Next Year | $6.32 | $16,285.34 |
| P/E Ratio | $701.75 | ★ N/A |
| Revenue Growth | ★ 6.84 | N/A |
| 52 Week Low | $9.46 | $0.39 |
| 52 Week High | $14.11 | $45.00 |
Technical Indicators
Market Signals| Indicator | NFBK | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 59.49 | 55.08 |
| Support Level | $13.23 | $21.27 |
| Resistance Level | $14.08 | $27.30 |
| Average True Range (ATR) | 0.21 | 1.71 |
| MACD | 0.02 | 0.43 |
| Stochastic Oscillator | 72.94 | 74.68 |
Price Performance
Historical Comparison NFBK
LYEL
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union, and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.